title: Indoleamine 2,3-dioxygenase vaccination.
abstract: Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.
authors.affiliation: Department of Hematology; Center for Cancer Immune Therapy (CCIT); Copenhagen University Hospital ; Herlev, Denmark.
authors.forename: Mads Hald
authors.initials: MH
authors.lastname: Andersen
authors.affiliation: Department of Hematology; Center for Cancer Immune Therapy (CCIT); Copenhagen University Hospital ; Herlev, Denmark ; Department of Oncology; Copenhagen University Hospital ; Herlev, Denmark.
authors.forename: Inge Marie
authors.initials: IM
authors.lastname: Svane
keywords: CD8; DC, dendritic cells; IDO; IDO, indoleamine 2,3-dioxygenase; NSCLC; NSCLC, non-small-cell lung cancer; OS, overall survival; PBMC, peripheral blood mononuclear cells; PD, progressive disease; PD-L1; SD, stable disease; Tregs, regulatory T cells; cancer vaccine